Semaglutide
The latest news about Semaglutide: headlines, AI summaries and the full story from every source.
- Regeneron and Novo Nordisk Combination Therapy Reduces Muscle Loss in Study
- Novo Nordisk CEO Warns About Patent Risk for Wegovy and Ozempic
- Novo Nordisk CEO Addresses Looming Patent Cliff for Ozempic
- Study Finds Weight-Loss Drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) Effective at Lower Doses
- Novo Nordisk Expands Obesity Drug to Children Amid Market Hesitation
- Novo Nordisk's Pediatric Obesity Drug Trial Shows Promise, But Commercial Success Uncertain
- Novo Nordisk Reports Positive Semaglutide Trial Results for Obesity Treatment in Children
- Dr. Reddy's Laboratories Reports Q1 Revenue Decline Amid Semaglutide and Lenalidomide Challenges
- Dr. Reddy's Laboratories Reports Semaglutide Supply Delay Due to API Validation Issue
- Dr Reddy's Laboratories Faces Share Price Drop Due to Semaglutide Supply Issues
- Hims Launches Generic Version of Novo Nordisk's Semaglutide in Canada
- First Ozempic Generics Approved in Canada, Seen as Test Case for Novo Nordisk
- FDA Proposes Excluding Novo Nordisk and Eli Lilly Weight Loss Drugs from Bulk Compounding List